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Abstract 
 
The isothiocyanate (ITC) sulforaphane (SFN) was shown at low levels (1-5 µM) to promote cell 
proliferation to 120-143% of the controls in a number of human cell lines, whilst at high levels 
(10-40 µM) it inhibited such cell proliferation. Similar dose responses were observed for cell 
migration, i.e. SFN at 2.5 µM increased cell migration in bladder cancer T24 cells to 128% 
whilst high levels inhibited cell migration. This hormetic action was also found in an 
angiogenesis assay where SFN at 2.5 µM promoted endothelial tube formation (118% of the 
control), whereas at 10-20 µM it caused significant inhibition. The precise mechanism by which 
SFN influences promotion of cell growth and migration is not known, but probably involves 
activation of autophagy since an autophagy inhibitor, 3-methyladenine, abolished the effect of 
SFN on cell migration. Moreover, low doses of SFN offered a protective effect against free-
radical mediated cell death, an effect that was enhanced by co-treatment with selenium. These 
results suggest that SFN may either prevent or promote tumour cell growth depending on the 
dose and the nature of the target cells. In normal cells, the promotion of cell growth may be of 
benefit, but in transformed or cancer cells it may be an undesirable risk factor.  In summary, 
ITCs have a biphasic effect on cell growth and migration. The benefits and risks of ITCs are not 
only determined by the doses, but are affected by interactions with Se and the measured 
endpoint.  
 
 
Keywords: cruciferous vegetables; isothiocyanate; sulforaphane; hormesis; NF-E2-related factor 
2; angiogenesis; cancer. 
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Introduction 
     The term ‘hormesis’ is often used by toxicologists to refer to a ‘biphasic dose response to an 
environmental agent characterized by low dose stimulation and by high dose inhibitory or toxic 
effect’ [1,2]. The hormesis concept is the most fundamental dose-response relationship in the 
biomedical, nutrition and toxicological sciences [1]. In a comprehensive review, Calabrese 
provided evidence that more than a hundred anti-tumour agents enhanced the proliferation of 
human tumour cells at low doses in a manner fully consistent with the hormetic dose-response 
relationship [2]. One of the interesting characteristics of such dose-responses was that they 
occurred in most types of tumour cells and were independent of organ. Recent findings suggest 
that some phytochemicals exhibit biphasic dose responses in cells with low doses activating 
signalling pathways that result in increased expression of genes encoding cytoprotective proteins 
and antioxidant enzymes [3]. The dietary hormetic compounds identified so far include 
resveratrol, epigallocatechin gallate (EGCG), curcumin, quercetin, allicin, capsaicin, carnosic 
acid and sulforaphane (SFN) [4-8]. From an evolutionary perspective, the noxious properties of 
phytochemicals have an important protective role in dissuading insects and fungi from damaging 
plants. However, the relatively small doses of phytochemicals ingested by humans that consume 
these plants are not toxic and instead induce mild cellular stress responses. This phenomenon has 
been widely described as ‘hormesis’ or adaptive dose response in the fields of biology and 
medicine [4,9,10].  
   The isothiocyanate (ITC), SFN (4-methylsulfinylbutylisothiocyanate), was first isolated from 
the commonly-consumed cruciferous vegetable, broccoli and is one of the most potent naturally-
occurring inducers of the Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid 
2-related factor 2 (Nrf2)-antioxidant response elements (ARE) pathway [11]. The induction of 
Nrf2 protects normal cells from free-radical mediated oxidative stress via upregulation of 
chemoprotective genes, and the action of SFN is based on its ability to induce a Nrf2-driven 
enzyme quinone reductase (NQO1) [12]. In the 20 years subsequent to its discovery, the 
protective effects of SFN have been demonstrated in various cell culture systems and animal 
models, with the result that SFN is by far the most extensively studied ITC from cruciferous 
vegetables.  The anti-carcinogenic mechanisms of ITCs have also been well-documented, 
including up-regulation of phase II detoxification enzymes, anti-inflammation, promotion of cell 
cycle arrest and apoptosis [13-17]. During the last decade, Keap1-Nrf2-ARE has been 
considered as a critical anti-cancer pathway in chemoprevention [18-20]. However, more 
recently, there have been some deleterious reports of Nrf2, including promotion of tumour cell 
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growth and chemoresistance [21-25]. In order to survive, cancer cells may hijack the Nrf2 
pathway which upregulates a battery of antioxidant enzymes, thereby maintaining a favourable 
redox balance in order to acquire malignant properties [26]. Overexpression of Nrf2 could 
enhance cell proliferation and cause resistance to chemotherapeutic interventions in some types 
of cancer, including human lung and pancreatic cancers [27,28]. A few previous investigations 
have shown that SFN exhibits a dose-dependent effects on cell proliferation in cultured tumour 
cell lines and normal cells including human mesenchymal stem cells [29-31]. In the present 
study, we showed that SFN exhibited a hormetic dose response on cell growth, migration and 
angiogenesis. Whether the hormetic effect is beneficial or harmful depends on the selected 
endpoint and/or the nature of the cells (normal or tumour). Although the term hormesis is 
employed by toxicologists to describe a bell-shaped dose response, characterized by a beneficial 
effect at low doses and a toxic (or inhibitory) activity at high doses, this expression of low dose 
benefit might not be true for the effect of ITCs in cancer chemoprevention. Since hormesis 
shows little selectivity, the biological effects of ITCs on normal cells and tumour cells will 
differ. From this perspective, a low dose effect of ITCs in promoting tumour cell proliferation 
and migration in animal models must be evaluated prudently. Thus, a precise strategy that aims 
to optimise the beneficial effects and minimise the risk of ITCs should be developed with care in 
relation to cancer prevention and treatment. 
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Results  
 
Effects of ITCs on cell growth 
   Due to the nature of the hormetic dose response, there is no selectivity of ITCs on cell growth, 
so it is likely that ITCs can promote tumour cell growth at low doses.  In several in vitro cell 
culture studies, low concentrations of SFN have been shown to promote tumour cell growth, but 
no detailed discussion or suggestions for follow-up studies to investigate the mechanisms were 
provided [32-34]. At low concentrations, ITCs have been shown to induce proliferation and/or 
protect cells against a toxic agent, H2O2, in Caco-2 cells [30] and in hepatocytes [29].  Fig. 1A 
shows the effects of SFN on cell growth, with lower doses (1-5 µM) promoting cell growth (20-
43% greater than the control) and high doses (10-40 µM) inhibiting cell growth in a number of 
tumour cell lines, namely, bladder cancer T24, hepatoma HepG2, and colon cancer Caco-2. 
Similar dose response effects were found in normal cell lines including immortalised hepatocyte 
HHL-5, colon epithelial CCD841 and skin fibroblast CCD-1092SK cell lines (Fig. 1B).  
 
Effects of SFN on cell migration 
   Fig. 2A shows a bell-shaped dose response of SFN on bladder cancer T24 cell migration. SFN 
at 2.5 and 3.75 µM increased tumour cell migration to 128 and 133% in comparison with 
corresponding controls. Such SFN-induced cell migration is associated with the ability of SFN to 
activate autophagy. When an autophagy inhibitor, 3-methyladenine (3-MA), was used it 
alleviated SFN (2.5 µM)-induced cell migration from 128 to 26% although it has less inhibitory 
effect on SFN treatments at 5 or 10 µM (Fig. 2B). Moreover, 3-MA also decreased the migration 
of non-SFN treated cells to 12% of the control.   
 
ITCs and activation of Nrf2 
   SFN is an activator of Nrf2 via which it can up-regulate more than a hundred protective genes, 
including most antioxidant and chemopreventive enzymes [11,35]. There is no doubt that up-
regulation of Nrf2-ARE pathway is beneficial in normal cells, i.e. activation of Nrf2 and its 
driven cytoprotective enzymes can be protective against oxidative damage and  it has been 
suggested that activation of the Nrf2 signalling pathway can thus be a promising strategy in 
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cancer prevention [36]. But, ITCs have no selectivity towards either normal or tumour cells with 
regards to Nrf2 activation. Nrf2 can be hijacked by tumour cells [26], and a recent report 
suggests that Nrf2 is a protooncogene which modulates tumour cell growth [37].  In transformed 
cells, Nrf2 may promote cell growth or cause chemoresistance [38]. In this study, SFN (2.5-10 
µM) induced similar levels of translocation of Nrf2 into the nucleus of normal human 
hepatocytes HHL-5 (4.1-7.1 fold), and hepatoma HepG2 (4.1-5.9 fold) cells (Fig. 3).  
 
Protective role of low dose ITC treatment against oxidative damage 
   In the fields of biology and medicine, hormesis is defined as an adaptive response of cells and 
organisms to a moderate stress. A mild stress induces the activation of signalling pathways such 
as Nrf2, NF-kB, Sirtuin, FOXO, hypoxia-inducible factor (HIF) thus leading to intrinsic changes 
(e.g. induction of antioxidant enzymes) that can confer resistance to more severe stress [4,6].  
Fig. 4A and 4B show that pretreatment of HHL-5 and MCF-7 cells with 5 µM SFN offered 
protection against H2O2-induced cell death, i.e. cell viability increased from 36.6 to 63.9%; and 
from 50.3 to 83.7% with 400 µM H2O2 treatments, respectively. Moreover, the protective effect 
of pretreatment with SFN (2 µM) on H2O2-induced cell death could be enhanced by cotreatment 
with selenium (Se) in HHL-5 cells (Fig. 4C), i.e. H2O2 decreased cell viability to 34.8% in HHL-
5 cells but when cells were pre-treated with SFN (2 µM), or Se (0.1 µM) for 24 h, the cell 
viability increased to 41.7 and 51%, respectively and co-treatment SFN and Se increased cell 
viability to 65.5%. This protective effect may be involved in either chemoprotection or 
chemoresistance, depending on the nature of the cells.   
 
Biphasic effects of SFN on angiogenesis  
   Angiogenesis (new blood vessel growth) is crucial in the development and spread of a variety 
of human cancers. It is, therefore, important to examine the anti-angiogenic effects of potential 
anti-cancer agents. In contrast, inadequate blood supply to the heart and other tissues, resulting 
from insufficient new blood vessel growth, is a feature of many cardiovascular diseases.  SFN 
has been shown to inhibit angiogenesis at high concentrations [39]. In this study, SFN at 2.5 µM 
promoted tube formation to 118% of the control, i.e. total tube length was 4.78 mm/mm2 in 
control and 5.65 mm/mm2 in SFN (2.5 µM) treated cells (Fig. 5). SFN at 5 µM showed a less 
significant promotion (111% relative to the control), whereas 10 and 20 µM SFN inhibited tube 
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formation significantly (decreased to 61 and 20% of the control, respectively).  SFN at low dose 
promoted the formation of a continuous basement membrane around endothelial tubes; whereas 
at high doses of SFN, fragmented basement membranes were found (Fig. 5A). These data 
suggest that for anti-angiogenesis a relatively high dose of SFN should be used since a lower 
dose may promote angiogenesis. However, the stimulating effect of low doses on new blood 
vessel formation could be beneficial in patients with cardiovascular diseases. 
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Discussion 
Hormetic effect of ITCs on cell growth, migration and angiogenesis 
   The hormetic zone concentrations (approximately 1-5 µM) of ITCs that are added in cell 
culture could readily be achieved in human plasma after consumption of a meal rich in 
cruciferous vegetables, or from extracts or supplements [40-44].  Table 1 shows the plasma 
levels of ITCs measured in several human studies (see also reference [45]).  SFN is derived from 
the action of the endogenous enzyme, myrosinase on the glucosinolate, glucoraphanin which is 
found in cruciferous vegetables. The glucosinolate contents of common Brassica are available 
from a database developed by McNaughton and Marks [46]. The highest glucosinolate value was 
from cress (389 mg/100g fresh weight) while the lowest value was from Chinese cabbage (20 
mg/100g fresh weight), although cultivar type and growing conditions both influence these 
figures. Broccoli contains 61.7 mg/100g (19.3-127.5mg glucoraphinin/100g) [46], which is 
equivalent to 141.3 µmol SFN/100g (44.2-292.1 µmol/100g fresh weight) if the conversion is 
100% efficient. Food processing and cooking conditions are crucial factors in influencing the 
activity of myrosinase, and subsequent formation of ITCs [47].  The main influence on the 
ensuing production of ITCs in vivo is how the brassica vegetables have been cooked [48]. 
Extensive studies of SFN have provided convincing evidence that SFN is a chemopreventive 
agent [49,50]; and the mechanisms of its action involves the induction of phase II enzymes, cell 
cycle arrest and apoptosis [16,51].  
   In general, findings from epidemiological studies on the association between vegetable intake 
and cancer risk are inconsistent. A high intake of cruciferous vegetables has, however, been 
shown to decrease the risk of several types of cancer, including those of colon and lung [52,53]. 
If the hormetic effects of ITCs are involved in cancer growth, the overall biological impact of 
cruciferous vegetable on cancer risk becomes much more complicated. However, if a low dose 
of ITCs promotes cancer cell growth it may help to explain why epidemiological studies do not 
show a consistent association between cruciferous vegetable intake and the risk of cancer. 
Therefore, it is crucial to understand the mechanisms of action of the hormetic effects of ITCs. In 
in vitro cell cultures, the mechanisms by which low doses of SFN promote cell growth may be 
related to the effect SFN has on the activation of growth promoting molecules (such as HER2, 
RAS, RAF, MEK, ERK, PI3K, AKT and mTOR), signal transduction pathways such as NF-kB, 
FOXO, HIF, Nrf2, autophagy and receptors [54-56].   
9 
 
     Autophagy involves the formation of double-membraned vesicles (autophagosomes), which 
encapsulate the cytoplasm and organelles and fuse with lysosomes, leading to degradation of the 
contents of the vesicle [57]. SFN is known to be an inducer of autophagy [58], but it is unclear 
how induction of autophagy is associated with suppression of cell migration. Other potential 
targets of SFN may include matrix metalloproteinases (MMPs), microtubules, collagens and 
integrins, survivin and zinc finger E-box binding homeobox 1 (ZEB1) [59]. A very recent study 
suggests that activation of autophagy is associated with chemoresistance, and that histone 
deacetylase (HDAC)10 protects neuroblastoma cells from cytotoxic agents by mediating 
autophagy [55]. This work indicates that co-treatment with HDAC10 inhibitor and a 
chemotherapeutic drug (doxorubicin) is a promising way to improve treatment response. Another 
study suggests that Notch activation is largely dispensable for SFN-mediated inhibition of cell 
migration in human prostate cancers [60], and this could be a therapeutic advantage as Notch 
activation is common in human prostate cancers.  High constitutive levels of Nrf2 occur in many 
tumours, whilst overexpression of Nrf2 in cancer cells protects them from the cytotoxic effects 
of anticancer therapies, resulting in chemoresistance [22,61]. There are interactions between 
ITCs and Se in the up-regulation of thioredoxin reductase (TR-1) and glutathione peroxidase 2 
(GPx2) [30] and it is clear that ITCs and Se exhibit a plethora of multi-targeted effects in cancer 
chemoprevention. Interestingly, Se also promotes the migration and invasion of prostate cancer 
PC3 cells [62].  
 
Assessment of the hormetic effect of ITCs 
      Consumption of cruciferous vegetables would not only provide ITCs but also contribute 
other nutrients and phytochemicals, including tocopherols, flavonoids, ascorbate and Se.  These 
components could counteract/interact with the prooxidant/antioxidant activities of ITCs. Based 
on the hormetic nature of ITCs, consumption of a quantity of cruciferous vegetables that provide 
a hormetic level of ITCs in plasma could be a risk factor for those who have transformed cells in 
the body. A schematic diagram for analysing the benefits and risks of dietary ITCs is proposed in 
Fig. 6. For all dietary compounds and toxic substances, “the dose makes the poison” [wording 
simplified from “all things are poison, and nothing is without poison; only the dose permits 
something not to be poisonous” (Paracelsus, 1493-1541)]. For dietary ITCs, there should be a 
“no effect level” prior to the detection of any biological effects. Indeed, the level of ITCs in the 
plasma of a majority of the population is likely to be much lower than sub-µM and may not exert 
any biological effects on cells.  However, following increased intakes, such as in the trials listed 
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in Table 1 or for individuals taking supplements, the plasma ITC levels could reach the hormetic 
zone concentrations. Typical characteristics of the hormetic zone (dose A-C) includes low 
concentrations stimulating and high concentrations inhibiting effects. For SFN, the hormetic 
zone is found to be 1-5 µM in the in vitro cell culture experiments, although the dose-effects 
found in vitro experiments should not be directly extrapolated to humans.  It is possible that the 
hormetic zone and the No Observed Adverse Effect Level (NOAEL, dose C) in humans is 
significantly different. In order to maximise the beneficial effect and minimise the risk, both 
genetic factors and interactions between dietary components should be considered. For example, 
genetic polymorphisms of glutathione transferases (GSTs) affect SFN metabolism and the risk of 
cancer [63]. On the other hand, supplementation with cruciferous vegetables increased GSTA1/2 
activity, the effect being most marked in GSTM1-null/GSTT1-null men [64]. Although there are 
currently few epidemiological studies that employ genotyping, research of this nature will 
increase in the future and it is likely the nutrigenetics will provide a basis for personalised 
medicine and nutrition. Interactions between bioactive phytochemicals and nutrients may 
contribute to the overall benefits and risks of ITCs depending on the health status of the 
individuals. The inductions of Nrf2 and antioxidant enzymes such as TR-1 could also be of 
either benefit or risk depending on the nature of the target cells (normal vs tumour). 
 
Where are we now? How can we maximise the benefits and minimise the risks?   
   Thirty years ago, researchers focused on the potential toxic (goitrogenic) properties of 
glucosinolate breakdown products [65].  In 1992, sulforaphane was isolated from broccoli and 
anti-carcinogenic studies were based on its potent activity in the induction of phase II enzymes 
[12,66]. Over the last decade, many Nrf2 inducers including ITCs, resveratrol, catechin, 
cucurmin, and quercetin have been reported [67,68] with both chemopreventive and oncogenic 
activities [69-71]. Recently, two Nrf2 inhibitors, brusatol (from the seeds of Brucea sumatrana) 
and trigonelline (from coffee) were reported to enhance the efficacy of anticancer therapy 
[72,73] . Moreover, Nrf2 knockdown has been shown to inhibit tumour growth, increase the 
efficacy of chemotherapy in cervical cancer [74], and inhibit the angiogenesis of rat cardiac 
micro-vascular endothelial cells under hypoxic conditions [75]. Therefore, it is clear that the role 
of Nrf2 in cancer development is a topic of controversy and Nrf2 activators such as SFN and 
other ITCs may contribute both benefits and risks in cancer development.  
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   An understanding of the complex plethora and divergent natures of ITCs and other dietary 
Nrf2 activators and their hormetic dose responses, combined with an accurate diagnosis (stage of 
cancer), and genetic analysis  may, in the not-too-distant future, initiate the significant potential 
that personalised medicine may have. New diagnostic techniques exploiting gold nanoparticles 
can spot tumour-like masses as small as 5 mm in the liver [76]. Gold nanoparticles with a 
polyelectrolyte coating can make even smaller tumours visible through X-ray scatter imaging, 
thereby enabling earlier diagnosis. Once tumours can be diagnosed at such a very early stage, a 
potential therapeutic approach could be the nanoencapsulation of cancer-fighting phytochemicals 
or drugs through monitored and targeted delivery [77]. But, it must be remembered that ITCs at 
high concentrations are also toxic towards normal cells. Adverse effects have been reported in in 
vitro studies using 10-30 µM SFN, including induction of DNA, RNA and mitochondrial 
damage [78-80].  Moreover, there was also a case report of liver toxicity in an individual who 
consumed 800 ml broccoli soup a day for 4 weeks [81]. Low levels of ITCs can generate reactive 
oxygen species (ROS), and activate Nrf2-ARE to switch on antioxidant enzymes. Although high 
levels of ROS can damage protein, lipids and DNA in cells, low levels of ROS can play an 
important role in immune defence, antibacterial action, vascular tone, and signal transduction 
[82]. Recently, James Watson hypothesised that diabetes, dementias, cardiovascular disease and 
some cancers are all linked to a failure to generate sufficient ROS [83]. The challenge is to 
define the balance between the generation of ROS and the antioxidant capacity in each type of 
cells. For dietary ITCs, it is important to define the optimal range of intakes for promoting 
health. Nevertheless, further human studies are required to establish the personalised optimal 
doses, safety and efficacy profiles using more sensitive biomarkers. 
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Materials and Methods 
Materials 
   Sulforaphane was purchased from Enzo Life Sciences (UK). Sodium selenite, 
dimethylsulfoxide (DMSO), hydrogen peroxide, Bradford reagent, methylthiazolyldiphenyl-
tetrazolium bromide (MTT), phenylmethylsulfonyl fluoride (PMSF), and all other materials and 
reagents were purchased from Sigma-Aldrich (UK). Rabbit polyclonal primary antibodies to 
Nrf2, Sam68 and horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG as secondary 
antibodies were all obtained from Santa Cruz Biotechnology Inc. (Heidelberg, Germany). Anti-
collagen IV and anti-human CD31/PECAM-1 were purchased from Millipore and BD 
Biosciences (UK), respectively. Secondary antibodies conjugated with Cy2 and Cy3 were 
purchased from Jackson Immuno Research (UK). Mini-complete proteinase inhibitor and WST-1 
reagent were purchased from Roche Applied Sciences (UK). Electrophoresis and Western 
blotting supplies were supplied by Bio-Rad (UK). The enhanced chemiluminescence (ECL) kit 
was purchased from GE Healthcare (UK). 
 
Cell culture 
   Immortalised human hepatocytes (defined as HHL-5) were kindly supplied by Dr Arvind Patel, 
Medical Research Council (MRC) Virology Unit (Glasgow, UK) [84]. All other cell lines were 
purchased from ATCC.  Cells were routinely cultured in DMEM supplemented with foetal 
bovine serum (10%), 2mM glutamine, penicillin (100 U/ml) and streptomycin (100 µg/ml) under 
5% CO2 in air at 37oC.  
 
Cell proliferation assay 
   The cell proliferation MTT assay was employed to detect the toxicity of SFN (1-160 µM) on 
cultured cells. When cells were at approximately 70–80% confluence, cells were exposed to 
various concentrations of SFN for different times using DMSO (0.1%) as control.  After all 
treatments, the medium was removed, 5 mg/ml MTT was added, and incubated at 37oC for 1 h to 
allow the MTT to be metabolized. Then the formazan produced was re-suspended in 100 µl 
DMSO per well.  The final absorbance in the wells was recorded using a microplate reader 
(BMG Labtech Ltd, UK) at a wavelength of 550 nm and a reference wavelength of 650 nm. 
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Cell migration assay 
   Cell migration was quantified using a ThinCert cell culture inserts cell migration assay 
(Greiner Bio-One Ltd.). After overnight starvation in serum free medium, cells were treated with 
various concentrations of SFN for 24 h, the cells migrating through a PET membrane were 
labelled fluorescently with Calcein-AM and quantified by microplate reader (BMG Labtech Ltd, 
UK) with an excitation wavelength of 485 nm and emission wavelength of 525 nm. 
 
Protein extraction and Western blot Analysis 
   For total protein, HHL-5 cells were washed twice with ice-cold PBS, harvested by scraping in 
20 mM Tris-HCl (pH 8), 150 mM NaCl, 2 mM EDTA, 10% glycerol, 1% Nonidet P40 (NP-40) 
containing mini-complete proteinase inhibitor. The cell suspensions were placed in an ice bath 
for 20 min and then centrifuged at 12,000 g for 15 min at 4oC. Supernatant was collected and the 
protein concentration determined by the Bradford Brilliant Blue G dye-binding assay of using 
BSA as a standard. For the nuclear protein, the extraction was performed by using a Nuclear 
Extract Kit (Active Motif, UK), following the manufacturer’s instructions.   
   Protein extracts were heated at 95°C for 5 min in loading buffer and loaded onto 10% SDS-
polyacrylamide gels together with a molecular weight marker. After routine electrophoresis and 
transfer, the polyvinylidene difluoride (PVDF) membrane was blocked with 5% fat free milk in 
PBST (0.05% Tween 20) for 1 h and incubated with a specific primary antibody in 5% milk in 
PBST for 1 h. The membrane was washed three times for 45 min with PBST and then incubated 
with the secondary antibody diluted with 5% milk in PBST for 1 h. After three further washes for 
45 min with PBST, the antibody binding was determined using an ECL kit (GE Healthcare, UK) 
and densitometry was measured by Fluor Chem Imager (Alpha Innotech, San Leandro, CA).  
 
Angiogenesis assay - tube formation in a 3-D model 
   Human umbilical vein endothelial cells (HUVEC) and pericytes (PVC) were co-cultured in 
collagen type I gel as described previously [85]. SFN (0-40 µM) was added to the medium (top 
of 3-D collagen gel) and the medium was changed every 24 h with fresh SFN added. At day 5, 
samples were fixed, immunostained with CD31 and collagen type IV and counterstained with 
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DAPI. Magnification pictures were taken from five random fields of each sample and average 
tube length measured.  
 
Statistics 
   Data are represented as the mean ± SD. The differences between the groups were examined 
using one-way ANOVA test, or student’s t-test. A p value <0.05 was considered to be 
statistically significant. IC50 values of SFN and H2O2 were determined using CalcuSyn Software 
(Biosoft, UK). 
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Conclusions and future perspectives 
   Based on findings from the research reported here, greater effort should be expended on the 
evaluation of the interactive/synergistic effects on the cancer risk of various phytochemicals and 
phytochemical-rich foods. Risk/benefit assessment of ITCs and other dietary bioactives may be 
linked to genotype, health status or tumour stage, and of course the dose, all of which must be 
included in future research priorities. More precise dietary guidelines and policies for cancer 
prevention could also be developed based on the understanding of these fundamental factors. 
There are at least five ongoing human trials using SFN or broccoli sprout preparations registered 
with http://www.clinicaltrials.gov/ and it will be of great interest to study the results in coming 
years. In the absence of precise knowledge in these areas, it is considered prudent to study the 
molecular mechanisms of the interactions between ITCs and other bioactives/nutrients in cell 
cultures and animal models prior to undertaking large, very expensive human trials. In this sense, 
β-carotene has been a good example.  In observational studies, high intake of carotenoids from 
food has been associated with reduced risk of cancer. However, observational studies are 
inherently unreliable and it would be a big mistake to conduct human trials without having 
sufficient information about the mechanisms of action in cells.  In intervention trials, β-carotene 
supplements have not been found to offer any benefits; in fact, when taken in high doses for a 
long period of time, they slightly increased the risk of some forms of cancer [86].  However, this 
is an area of activity that is rapidly developing and this assessment may well need to be revisited 
in the light of emerging scientific data. These results show that low concentrations of ITCs 
especially SFN may be potentially beneficial or harmful, depending on the endpoint of interest 
and the cell type, i.e. beneficial to normal angiogenesis and harmful in promotion of cancer cell 
growth. SFN is important because it is present in our normal diet from cruciferous vegetables 
and also because of its commercial applications (there are many different brands of broccoli 
extracts marketed as supplements). Based on the hormetic dose response, nutraceutical producers 
should carefully consider the efficacy of the application of ITC/SFN-rich products/supplements. 
On the basis of their biphasic effects on cell growth and migration, there is no doubt that ITCs 
belong to the so-called hormetic class of phytochemicals. 
   In summary, low concentrations of ITCs can potentially be either beneficial or harmful. Since 
there is little selectivity in the hormetic effect, the benefits or risks of ITCs at lower doses could 
be different in normal and tumour cells. In tumour cells, low doses of SFN could have the 
capability to increase the risk of tumour development.  In contrast, in normal endothelial cells, 
SFN could be significantly cardio-protective (angiogenetic). This type of conflict between 
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beneficial and harmful effects is not uncommon and may be related to the different biological 
systems, tissues and chemical agents under investigation [87]. The evidence regarding the 
hormetic dose response induced by SFN is obvious, but the relevant molecular mechanisms are 
not fully understood, and thus deserve greater attention in future research. Nutrition scientists 
and oncologists should be aware of the potential risks of dietary ITCs, especially of the possible 
role of hormesis if they are used as food supplements.  Finally, the majority of the available 
evidence described above is based on in vitro cell culture experiments. Research is also needed 
to evaluate the relative risks, as well as benefits, of the hormetic effects in medium- to long-term 
supplementation with dietary ITCs and other phytochemicals in animal studies and small scale 
human trials. 
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Figure legends 
 
Fig. 1. Effects of SFN on the proliferation of normal and tumour cells.  
When cells grew to 70–80% confluence, a range of doses of SFN (0-160 µM) were added to the cell 
culture medium for 24-48 h. The control cells were treated with DMSO (0.1%), and cell viability was 
determined by the MTT cell proliferation assay (CCD-1092SK cell viability was determined by WST-1 
assay according to manufacturer’s instructions [88]). Each data point represents the mean ± SD of at least 
5 replicates. Statistical significance from the control, *p< 0.05, or **p<0.01. A: results from bladder 
cancer T24, hepatoma HepG2, and colon cancer Caco-2 cells.  B: Results from immortalised hepatocyte 
HHL-5, colon epithelial CCD841, and skin fibroblast CCD-1092SK cell lines. 
 
Fig. 2.  Effects of SFN and 3-MA on cell migration.  
A: After starvation overnight, bladder cancer T24 cells were treated with SFN at the concentrations 
indicated for 24 h, cell migration was measured by a cell migration assay using the ThinCert cell culture 
inserts (Greiner Bio-One Ltd.). Each bar represents the mean ± SD of 3 replicates. B: Effect of pre-
treatment of 3-MA on cell migration. DMSO (0.1% was used as a control). Statistical significance from 
the control, *p<0.05, or **p<0.01. 
 
Fig. 3. Effect of SFN on translocation of Nrf2 into cell nucleus.  
Nrf2 was detected in nuclear extracts from cells exposed to SFN (0, 2.5, 5 and 10 µM) for 24 h, using a 
Western blot assay. Control cells were treated with DMSO (0.1%). A: immortalised human hepatocyte 
HHL-5; B: human heptoma HepG2 cells. 
 
Fig. 4. Effect of pre-treatment of cells with SFN protect against H2O2-induced cell death.  
Cells were cultured in 96 well plates. When they reached 70–80% confluence, cells were pre-treated with 
SFN (5 µM) for 24 h (HHL-5, A) or 48 h (MCF-7, B). The cell culture medium was replaced with H2O2 
at the concentrations indicated for a further 24 h.  C: HHL-5 cell were pre-treated with SFN (2 µM) and 
Se (0.1 µM) for 24 h before exposure to H2O2 (400 µM) for a further 24 h.  The cell viability was 
measured using MTT assay.  Statistical significance from corresponding controls: *p<0.05; **p<0.01. 
 
Fig. 5. Effect of SFN on endothelial tube formation in a 3-D angiogenesis assay.  
Culture medium supplemented with SFN (0-40 µM) was added to the top of 3-D collagen gels and then 
changed every 24 h with fresh SFN added. 3-D gels were fixed at day 5, immunostained with CD31 (red) 
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and collagen type IV (green), and counterstained with DAPI (blue). (A): Low magnification pictures were 
taken from five random fields of each sample and calculated for average tube length. (B) Representative 
pictures are shown in triple staining with higher magnification. Data are expressed as mean ± SD (n=5) 
(C). *P<0.05; ** P<0.01 compared to untreated control. 
 
Fig. 6. A schematic diagram on the hormetic effect of ITCs. 
For all cell types, dosage range 0-A is safe. In the majority of diets, the intakes of hormetic 
phytochemicals are likely to fall within this safe range.  For normal cells, dose B could be used 
promote new blood vessel formation or promote wound healing; doses >C are toxic. For tumour 
cells, doses between A and C should be avoided; and doses >C to D could be used for 
chemotherapy.  
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Table 1.  Human studies with plasma levels of dietary ITCs 
Study type Subjects 
(n) 
 
Dose Plasma conc. 
(µM) 
Refs 
Metabolisms, 
pharmacokinetics  
4 200 µmol ITCs (largely SFN) 0.94-2.27 Ye et al., 
2002 [40]. 
Metabolism 16 GST(+): 107 & 345.8 µmol SFN; 
GST(-): 95 & 342 µmol SFN 
2.2; 7.3 
2.3; 7.4 
Gasper et al., 
2005 [41]. 
Metabolism 
 
4 70 or 120 µmol SFN 0.9 or 2.1 Cramer et al., 
2011 [42]. 
Bioavailability 12 150 µmol glucoraphanin 2.2 Clarke et al., 
2011 [43]. 
Pharmacokinetics 4 100 g watercress 0.928 (±0.25) Ji et al., 2003 
[44]. 
 
